Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation

Patent Number: 7,199,162

During bone marrow or peripheral blood stem cell transplant, it is typical to perform preconditioning of the recipient. This is done in order to wipe out host derived hematopoiesis, and to "make room" for the donor stem cells. Additionally, in conditions of hematological neoplasia, recipient conditioning is performed with the idea of eradicating cancer cells.

Numerous protocols and procedures are available for host conditioning prior to stem cell tranplant. The current patent covers the use of the alkylating agent treosulfan. Various concentrations of treosulfan, as well as combinations between treosulfan and other drugs and treatments are covered.

View this patent on the USPTO website.